These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 24355795

  • 1. Inflammatory cytokines in Paget's disease of bone.
    Werner de Castro GR, Buss Z, Da Rosa JS, Fröde TS.
    Int Immunopharmacol; 2014 Feb; 18(2):277-81. PubMed ID: 24355795
    [Abstract] [Full Text] [Related]

  • 2. The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease.
    Neale SD, Schulze E, Smith R, Athanasou NA.
    QJM; 2002 Apr; 95(4):233-40. PubMed ID: 11937650
    [Abstract] [Full Text] [Related]

  • 3. Increased circulating Dickkopf-1 in Paget's disease of bone.
    Marshall MJ, Evans SF, Sharp CA, Powell DE, McCarthy HS, Davie MW.
    Clin Biochem; 2009 Jul; 42(10-11):965-9. PubMed ID: 19389391
    [Abstract] [Full Text] [Related]

  • 4. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
    Martini G, Gennari L, Merlotti D, Salvadori S, Franci MB, Campagna S, Avanzati A, De Paola V, Valleggi F, Nuti R.
    Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
    [Abstract] [Full Text] [Related]

  • 5. Alterations in vitamin D metabolites during treatment of Paget's disease of bone with calcitonin or etidronate.
    Devlin RD, Gutteridge DH, Prince RL, Retallack RW, Worth GK.
    J Bone Miner Res; 1990 Nov; 5(11):1121-6. PubMed ID: 2125401
    [Abstract] [Full Text] [Related]

  • 6. Proinflammatory cytokine gene polymorphisms and susceptibility to Paget's disease of bone: an association study.
    Gallone S, Di Stefano M, Fenoglio P, Rubino E, Criasia A, Pinessi L, Isaia G, Rainero I.
    Cytokine; 2011 Dec; 56(3):560-3. PubMed ID: 21917472
    [Abstract] [Full Text] [Related]

  • 7. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease.
    Meier C, Meinhardt U, Greenfield JR, De Winter J, Nguyen TV, Dunstan CR, Seibel MJ.
    Clin Lab; 2006 Dec; 52(1-2):1-10. PubMed ID: 16506358
    [Abstract] [Full Text] [Related]

  • 8. Circulating and tissue-derived isoforms of bone alkaline phosphatase in Paget's disease of bone.
    Magnusson P, Davie MW, Sharp CA.
    Scand J Clin Lab Invest; 2010 Apr; 70(2):128-35. PubMed ID: 20175736
    [Abstract] [Full Text] [Related]

  • 9. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L, Guañabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, Martinez de Osaba MJ, Muñoz-Gomez J, Rivera-Fillat F, Ballesta AM.
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [Abstract] [Full Text] [Related]

  • 10. Sarcoma arising in Paget's disease of bone: declining incidence and increasing age at presentation.
    Mangham DC, Davie MW, Grimer RJ.
    Bone; 2009 Mar; 44(3):431-6. PubMed ID: 19064007
    [Abstract] [Full Text] [Related]

  • 11. Serum osteocalcin concentrations in Paget's disease of bone.
    Wilkinson MR, Wagstaffe C, Delbridge L, Wiseman J, Posen S.
    Arch Intern Med; 1986 Feb; 146(2):268-71. PubMed ID: 3484940
    [Abstract] [Full Text] [Related]

  • 12. Paget's disease of bone in a patient on hemodialysis.
    Etemadi J, Bagheri N, Falaknazi K, Ardalan M, Rahbar K, Nobakht Haghighi A, Mohajel Shoja M.
    Iran J Kidney Dis; 2008 Apr; 2(2):105-7. PubMed ID: 19377219
    [Abstract] [Full Text] [Related]

  • 13. Metabolic-dependent increase of serum beta 2-microglobulin levels in patients with Paget's disease of bone.
    Fiore CE, Foti R, Tamburino C.
    Horm Metab Res; 1992 Mar; 24(3):143-4. PubMed ID: 1577406
    [No Abstract] [Full Text] [Related]

  • 14. Bone alkaline phosphatase in Paget's disease.
    Deftos LJ, Wolfert RL, Hill CS.
    Horm Metab Res; 1991 Nov; 23(11):559-61. PubMed ID: 1816067
    [Abstract] [Full Text] [Related]

  • 15. Paget's disease of bone: presentation, extent and response to bisphosphonates.
    Wang LM, Au-Yeong ML, McKenna MJ.
    Ir Med J; 2002 Sep; 95(8):244, 246. PubMed ID: 12405502
    [Abstract] [Full Text] [Related]

  • 16. Pain in Paget's disease: a retrospective study of treatment efficacy.
    Zati A, Colori BC, Bonfiglioli Stagni S, Mignani A.
    Neuro Endocrinol Lett; 2011 Sep; 32(2):127-32. PubMed ID: 21552192
    [Abstract] [Full Text] [Related]

  • 17. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD.
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [Abstract] [Full Text] [Related]

  • 18. Paget's disease of bone in New Zealand: continued decline in disease severity.
    Cundy HR, Gamble G, Wattie D, Rutland M, Cundy T.
    Calcif Tissue Int; 2004 Nov; 75(5):358-64. PubMed ID: 15455187
    [Abstract] [Full Text] [Related]

  • 19. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J.
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [Abstract] [Full Text] [Related]

  • 20. Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern Italy.
    Rendina D, Gennari L, De Filippo G, Merlotti D, de Campora E, Fazioli F, Scarano G, Nuti R, Strazzullo P, Mossetti G.
    J Bone Miner Res; 2006 Dec; 21(12):1828-35. PubMed ID: 17002563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.